Vivaldi Capital Management’s Galectin Therapeutics GALT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $364K | Buy |
172,443
+116,815
| +210% | +$246K | 0.05% | 196 |
|
|
2025
Q1 | $67.9K | Buy |
55,628
+10,000
| +22% | +$12.2K | 0.01% | 279 |
|
|
2024
Q4 | $55.7K | Buy |
45,628
+21,596
| +90% | +$26.3K | 0.01% | 283 |
|
|
2024
Q3 | $66.1K | Hold |
24,032
| – | – | 0.02% | 224 |
|
|
2024
Q2 | $54.3K | Hold |
24,032
| – | – | 0.02% | 228 |
|
|
2024
Q1 | $72.8K | Buy |
24,032
+4,771
| +25% | +$14.5K | 0.02% | 219 |
|
|
2023
Q4 | $32.6K | Hold |
19,261
| – | – | 0.01% | 219 |
|
|
2023
Q3 | $37K | Hold |
19,261
| – | – | 0.01% | 193 |
|
|
2023
Q2 | $27.7K | Hold |
19,261
| – | – | 0.01% | 200 |
|
|
2023
Q1 | $40.4K | Hold |
19,261
| – | – | 0.01% | 200 |
|
|
2022
Q4 | $22.5K | Hold |
19,261
| – | – | 0.01% | 241 |
|
|
2022
Q3 | $30K | Buy |
19,261
+2,183
| +13% | +$3.4K | 0.01% | 220 |
|
|
2022
Q2 | $22K | Hold |
17,078
| – | – | 0.01% | 216 |
|
|
2022
Q1 | $23K | Buy |
17,078
+6,410
| +60% | +$8.63K | 0.01% | 213 |
|
|
2021
Q4 | $22K | Hold |
10,668
| – | – | 0.01% | 207 |
|
|
2021
Q3 | $41K | Hold |
10,668
| – | – | 0.01% | 333 |
|
|
2021
Q2 | $36K | Hold |
10,668
| – | – | 0.01% | 343 |
|
|
2021
Q1 | $45K | Sell |
10,668
-4,771
| -31% | -$20.1K | 0.01% | 357 |
|
|
2020
Q4 | $35K | Hold |
15,439
| – | – | 0.01% | 301 |
|
|
2020
Q3 | $42K | Hold |
15,439
| – | – | 0.01% | 275 |
|
|
2020
Q2 | $40K | Buy |
15,439
+4,771
| +45% | +$12.4K | 0.01% | 259 |
|
|
2020
Q1 | $21K | Hold |
10,668
| – | – | ﹤0.01% | 195 |
|
|
2019
Q4 | $31K | Hold |
10,668
| – | – | 0.01% | 209 |
|
|
2019
Q3 | $39K | Hold |
10,668
| – | – | 0.01% | 216 |
|
|
2019
Q2 | $44K | Buy |
+10,668
| New | +$44K | 0.01% | 227 |
|